Cardiol Therapeutics Advances CardiolRx into Phase III Trial for Recurrent Pericarditis Following Positive Phase II Results
Key Insights
Cardiol Therapeutics is advancing its drug, CardiolRx, into a Phase III clinical trial (MAVERIC-3) for recurrent pericarditis (search) after promising Phase II results.
The Phase II MAvERIC-Pilot study demonstrated sustained reductions in pericarditis (search) pain and inflammation over 26 weeks with CardiolRx treatment.
A parallel Phase II/III trial (MAVERIC-2) will assess CardiolRx in recurrent pericarditis (search) patients after interleukin-1 (search) blocker therapy cessation.
Cardiol Therapeutics Inc. (CRDL:TSX; CRDL:NASDAQ) is moving forward with a Phase III clinical trial (MAVERIC-3) for its drug CardiolRx, aimed at treating recurrent pericarditis (search). This decision follows the presentation of positive results from the Phase II MAvERIC-Pilot study at the American Heart Association Scientific Sessions 2024, which demonstrated marked improvements in pericarditis pain and inflammation among patients treated with CardiolRx.
The MAvERIC-Pilot study, which enrolled 27 participants, revealed that the benefits observed at the eight-week primary endpoint were sustained throughout the 26-week extension period. Patients in the study had an average age of 53 years, with 67% being female. Before entering the trial, participants experienced an average disease duration of 2.7 years and 5.8 pericarditis (search) episodes per year.
Sustained Efficacy and Safety
Dr. S. Allen Luis, co-director of the Pericardial Diseases Clinic at the Mayo Clinic, highlighted the clinical relevance of the findings. "The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis (search) pain and C-reactive protein levels that were maintained throughout the study," said Luis. He also noted a substantial reduction in pericarditis episodes per year compared to the patients' historical event rate prior to the study, emphasizing the treatment's safety and tolerability in a population with significant disease burden.
Analyst Endorsements
Following the release of the Phase II results, Leede Financial Inc. analyst Dr. Douglas Loe maintained a Speculative Buy rating on Cardiol with a target price of CA$11.00. Loe emphasized the sustained efficacy of CardiolRx, noting that patients exhibited sustained pain relief, with average pain scores declining from 5.8 at enrollment to 1.5 at the six-month analysis. The analyst also pointed out that MAvERIC eight-week NRS data compares favorably to rilonacept's NRS data at the equivalent timepoint in the RHAPSODY trial.
Parallel Phase II/III Trial
Cardiol Therapeutics is also planning to initiate the MAvERIC-2 phase II/III trial, which will evaluate the impact of CardiolRx in recurrent pericarditis (search) patients following cessation of interleukin-1 (search) blocker therapy. This trial is expected to run in parallel with the MAVERIC-3 phase III trial.
Market Opportunity
The global market for cardiovascular drugs is projected to grow from US$149.99 billion in 2024 to US$207.78 billion by 2033, representing a CAGR of 4%, according to Precedence Research. This growth is driven by the increasing prevalence of heart-related conditions, including pericarditis (search), arrhythmias (search), coronary artery disease (search), hypertension (search), and heart failure (search).